A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV.

ABSTRACT:

Objectives

People living with HIV (PWH) experience an increased burden of coronary artery disease (CAD) believed to be related, in part, to an interplay of chronically increased inflammation and traditional risk factors. Recent trials suggest cardiovascular benefits of the anti-inflammatory, colchicine, in HIV-seronegative CAD patients. However, the impact of colchicine on impaired vascular health, as measured by coronary endothelial function (CEF), an independent contributor to CAD, has not been studied in PWH. We tested the hypothesis that colchicine improves vascular health in PWH.

Design

This was a randomized, placebo-controlled, double-blinded trial in 81 PWH to test whether low-dose colchicine (0.6 mg daily) improves CEF over 8-24 weeks.

Methods

Coronary and sys

SUBMITTER: Hays AG 

PROVIDER: S-EPMC8916096 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature